Bajpai Vijeta, Patel Tejas K, Dwivedi Priyanka, Bajpai Amrita, Gupta Astha, Gangwar Pradeepika, Singh Yashpal, Agarwal Richa, Kishore Surekha
All India Institute of Medical Sciences, Department of Anaesthesiology, Gorakhpur, India.
All India Institute of Medical Sciences, Department of Pharmacology, Gorakhpur, India.
Braz J Anesthesiol. 2023 Sep-Oct;73(5):665-675. doi: 10.1016/j.bjane.2022.07.005. Epub 2022 Jul 30.
This meta-analysis aimed to compare the efficacy and safety of dexmedetomidine and clonidine as an adjuvant to local anesthetics in BPBs.
Two investigators independently searched databases to identify all RCTs comparing the efficacy and/or safety of dexmedetomidine and clonidine as an adjuvant to local anesthetics in BPBs. All outcomes were pooled using the inverse variance method with a random-effect model. An I test was used to assess heterogeneity. The source of heterogeneity was explored through meta-regression. The quality of the evidence was assessed using the GRADE approach.
Out of 123 full texts assessed, 24 studies (1448 patients) were included in the analysis. As compared to clonidine, dexmedetomidine groups showed significantly longer sensory block duration (MD = 173.31; 95% CI 138.02‒208.59; I = 99%; GRADE approach evidence: high); motor block duration (MD = 158.35; 95% CI 131.55‒185.16; I = 98%; GRADE approach evidence: high), duration of analgesia (MD = 203.92; 95% CI 169.25‒238.58; I = 99%; GRADE approach evidence- high), and provided higher grade quality of block (RR = 1.97; 95% CI 1.60‒2.41; I = 0%; GRADE approach evidence: moderate). The block positioning technique (regression coefficient: 51.45, p = 0.005) was observed as a significant predictor of the heterogeneity in the case of sensory block duration. No significant difference was observed for the risk of hypotension (RR = 2.59; 95% CI 0.63‒10.66; I = %).
Moderate to high-quality evidence suggests dexmedetomidine is a more efficacious adjuvant to local anesthetic in BPBs than clonidine.
本荟萃分析旨在比较右美托咪定和可乐定作为局部麻醉辅助药物用于臂丛神经阻滞(BPBs)的有效性和安全性。
两名研究者独立检索数据库,以确定所有比较右美托咪定和可乐定作为局部麻醉辅助药物用于BPBs的有效性和/或安全性的随机对照试验(RCTs)。所有结局采用随机效应模型的逆方差法进行汇总。采用I²检验评估异质性。通过Meta回归探索异质性来源。采用GRADE方法评估证据质量。
在评估的123篇全文中,24项研究(1448例患者)纳入分析。与可乐定相比,右美托咪定组感觉阻滞持续时间显著更长(MD = 173.31;95%CI 138.02‒208.59;I² = 99%;GRADE方法证据:高);运动阻滞持续时间(MD = 158.35;95%CI 131.55‒185.16;I² = 98%;GRADE方法证据:高)、镇痛持续时间(MD = 203.92;95%CI 169.25‒238.58;I² = 99%;GRADE方法证据:高),且阻滞质量等级更高(RR = 1.97;95%CI 1.60‒2.41;I² = 0%;GRADE方法证据:中等)。在感觉阻滞持续时间方面观察到阻滞定位技术(回归系数:51.45,p = 0.005)是异质性的显著预测因素。低血压风险未观察到显著差异(RR = 2.59;95%CI 0.63‒10.66;I² = %)。
中高质量证据表明,在BPBs中,右美托咪定作为局部麻醉辅助药物比可乐定更有效。